SB 202190: Selective p38 MAP Kinase Inhibitor for Inflammation & Cancer

Executive Summary: SB202190 (FHPI, CAS 152121-30-7) is an ATP-competitive, cell-permeable pyridinyl imidazole compound that inhibits p38α (IC₅₀ = 50 nM) and p38β (IC₅₀ = 100 nM) MAP kinases with nanomolar potency [source_type: product_spec; source_link]. It blocks downstream phosphorylation events in the MAPK pathway, suppresses pro-inflammatory cytokine production, and induces apoptosis in select cancer cell lines. Animal studies have demonstrated neuroprotective effects in models of vascular dementia. SB202190 is widely used in inflammation research, apoptosis assays, and cancer therapeutics research as a tool compound for dissecting p38 MAPK function [source_type: paper; source_link].

Biological Rationale

Mitogen-activated protein kinases (MAPKs) mediate cellular responses to stress, cytokines, and growth factors. The p38 MAPK family, particularly isoforms p38α and p38β, orchestrates pro-inflammatory signaling, apoptosis, and proliferation. Dysregulated p38 signaling is implicated in chronic inflammation, cancer progression, and neurodegenerative diseases [DOI]. SB202190 selectively targets these isoforms, enabling precise experimental dissection of MAPK-dependent pathways. Unlike broad-spectrum kinase inhibitors, SB202190's specificity minimizes off-target effects, supporting its use in both mechanistic studies and preclinical disease models [source_type: product_spec; source_link]. This article extends prior benchmarks by systematically reviewing recent findings on SB202190 and highlighting technical nuances relevant for inflammation and cancer research, as contrasted with previous summaries that focus primarily on general usage guidance.

Mechanism of Action of SB202190 (FHPI)

SB202190 is a competitive inhibitor that binds to the ATP-binding site of p38α and p38β MAP kinases, with dissociation constant (K_d) for p38 MAPK of 38 nM [source_type: product_spec; source_link]. By blocking ATP access, it prevents substrate phosphorylation and downstream activation of inflammatory and apoptotic pathways. This inhibition suppresses the phosphorylation of targets such as MAPKAPK-2 and ATF2, attenuating cytokine production and modulating cell fate decisions. Notably, SB202190 exerts minimal activity against p38γ/δ, ERK, or JNK kinases at recommended concentrations, validating its selectivity [source_type: product_spec; source_link].

Recent mechanistic research emphasizes the relevance of the p38 MAPK axis in integrating signals that regulate RIPK1-dependent apoptosis and necroptosis, providing a conceptual bridge between kinase inhibition and cell death pathway modulation [DOI].

Evidence & Benchmarks

• SB202190 inhibits p38α with an IC₅₀ of 50 nM and p38β with an IC₅₀ of 100 nM under cell-free kinase assay conditions [source_type: product_spec; source_link].
• ATP-competitive binding is confirmed by a dissociation constant (K_d) of 38 nM for p38 MAPK [source_type: product_spec; source_link].
• In cell culture, 5 μM SB202190 for 72 hours robustly suppresses pro-inflammatory cytokine expression (e.g., IL-6, TNF-α) [source_type: workflow_recommendation; source_link].
• SB202190 induces apoptosis in select cancer cell lines, with effects corroborated by increased caspase-3 activation and DNA fragmentation [source_type: paper; source_link].
• In a rat vascular dementia model, intracerebroventricular injection of SB202190 reduced hippocampal neuronal apoptosis and improved spatial memory [source_type: paper; source_link].
• SB202190 has been benchmarked against other p38 inhibitors in studies of MAPK signaling, with superior selectivity and lower cytotoxicity at recommended doses [source_type: product_spec; source_link].

This article provides a more detailed breakdown of validated dosing regimens and model-specific benchmarks than the overview at MAP Kinase Fragment, which summarizes broader utility in inflammation and cancer research.

Applications, Limits & Misconceptions

SB202190 is extensively used in:

• Inflammation research: to dissect p38-dependent cytokine responses.
• Cancer therapeutics research: to study apoptosis, proliferation, and tumor–stroma signaling.
• Apoptosis assay workflows: as a reference compound for MAPK pathway inhibition.
• Vascular dementia models: for neuroprotection and memory function studies.

However, SB202190 is not a pan-MAPK inhibitor and does not target JNK or ERK at relevant concentrations. It is not recommended for use as a chronic in vivo therapy due to solubility and pharmacokinetic limitations [source_type: workflow_recommendation; source_link]. This article clarifies technical constraints not covered in the broader scenario-based guide provided by EprinomectinSource.

Common Pitfalls or Misconceptions

• Assuming SB202190 inhibits all MAPK isoforms: It is selective for p38α/β, not p38γ/δ, ERK, or JNK [source_type: product_spec; source_link].
• Using water as solvent: SB202190 is insoluble in water but soluble in DMSO (≥57.7 mg/mL) and ethanol (≥22.47 mg/mL) [source_type: product_spec; source_link].
• Long-term storage of working solutions: Solutions in DMSO should be stored below -20°C and are not recommended for long-term storage [source_type: product_spec; source_link].
• Overinterpreting in vivo efficacy: SB202190 is a research tool, not a clinically approved drug [source_type: workflow_recommendation; source_link].
• Assuming complete pathway blockade: Residual MAPK activity may persist depending on cell type and dosing [source_type: paper; source_link].

Workflow Integration & Parameters

Protocol Parameters

• apoptosis assay | 5 μM, 72 hours | cell culture | optimal for p38α/β inhibition without cytotoxicity | workflow_recommendation
• inflammation model | 1–10 μM, 24–72 hours | cell-based | dose range validated for cytokine suppression | product_spec
• animal neuroprotection | 10 μg, intracerebroventricular | rat | neuroprotection in hippocampal apoptosis | paper
• stock solution | ≥10 mM in DMSO | storage | stable for several months below -20°C | product_spec
• solubility | 57.7 mg/mL in DMSO; 22.47 mg/mL in ethanol | preparation | ensures adequate working stock concentration | product_spec

For detailed, scenario-driven guidance on assay integration and troubleshooting, see this robust workflow guide, which SB202190's protocol section here updates with recent benchmarking data.

Conclusion & Outlook

SB202190 (FHPI, SKU A1632) from APExBIO remains a gold-standard small molecule for studying p38α/β MAP kinase signaling in inflammation, cancer, and neuroprotection. Its selectivity, potency, and validated protocols enable reproducible modulation of apoptosis and cytokine pathways. Recent mechanistic studies underscore its value in apoptosis and necroptosis research and its limitations as a tool compound. Future research will continue to refine its application in disease modeling and pathway dissection, building on the foundational evidence summarized above [DOI].

For full specifications, handling protocols, and ordering information, access the SB202190 (FHPI) product page.